"Data from 160 patients at 17 sites was analysed. Median follow-up was 36.5 months." "A total of 63 of 160 (39%) patients remain on treatment." "A total of 17 of 160 (11%) discontinued treatment due to toxicity, with no treatment related deaths."
"A total of 56% of patients had at least 1 dose reduction, with neutropenia (68%) and abnormal liver enzymes (17%) the most common reasons."
"Median PFS (progression-free survival) was not reached, with PFS at 12 months and 18 months being 76% and 67%".
CONCLUSION: "The ribociclib and AI combination was well tolerated in this real-world setting." "The KARMA registry cohort achieved a superior PFS (>36.5 months) to MONALEESA-2, potentially due to more favourable baseline disease characteristics. Less frequent assessment scheduling in this non trial setting may also contribute."
"Compared to MONALEESA-2, patients were numerically younger (54.3 vs. 62 years), with higher rates of bone-only metastases (31% vs. 21%)." The PFS in MONALEESA-2 was 25.3 months.
Written by
Hazelgreen
To view profiles and participate in discussions please or .
hello- I was wondering about your post- did you come off Ibrance due to toxicity - and then go back on lower dose that now works for you? I am on .75 Ibrance and an AI anastrozole - i believe I am starting my 5th cycle- but they are trying 21 days in and 14 days off due to low neutrophils and feeling unwell - it seems the last week of the cycle I get very fatigued and not well, so there are apparently different methods now- some are 2 weeks on and a week off - wondering if you felt any bad side effects to start and now your system is tolerating it- it seems the lower dose works as well for lots of us -
I was initially on kisqali and letrozole but was pulled off kisqali after a couple of cycles because my ALT liver count went up to 285 (supposed to be less than 35) and then maxed out at 525 a couple of weeks after stopping the drug.
I also have issues with low neutrophils- when I was on chemo, on kisqali, and still now that I’m on ibrance. But always just on the cusp. But I don’t notice any side effects from it.
It took 5 months for my ALT to come back into range (only taking letro during this time) and then I started at 75mg of ibrance in September. 3 weeks on 1 week off.
My counts were good after that cycle so my oncologist bumped me up to 100mg and then after that cycle, I was bumped up to 125mg. Which I have have been on for 3 cycles now. I still have low neutrophils but they are at a consistent level so we’re carrying on. I get a small rash on the insides of my wrists for a few days in the 3rd week but other than that, I don’t have any side effects.
Not sure about energy level yet as I’m not back to work yet, so there’s not much competing for my time.
Scans have all shown improvement/stability so I’m thrilled with that. Bloodwork is monthly at this point but I hope to move to every three months after my blood draw next Monday 🤞🏻
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
